Medical Device Plasticizer Compliance: ISO 10993, FDA 510(k) & EU MDR Explained
The plasticizer isn't approved - the device is. Here's the framework, and where your material choice counts.
Picking a non-phthalate, low-migration plasticizer is a strong start for a medical PVC device - but it is not the finish line. A plasticizer is never "approved" on its own; the finished device is what has to clear biological evaluation and regulatory review. The good news is that plasticizer choice heavily influences whether that review goes smoothly. Here's the framework, and where your material decision actually moves the needle. 📋
🔑 The key idea
Compliance is assessed at the device and material level, not the raw-ingredient level. But a non-CMR, low-migration plasticizer reduces two of the biggest burdens - leachables to characterise and substances of concern to justify - so the right choice makes the whole path easier.
🔬 ISO 10993 - biological evaluation of medical devices
The cornerstone standard is ISO 10993-1, which sets a risk-based approach to biological safety inside the ISO 14971 risk-management process. Rather than a fixed checklist, it asks you to evaluate what matters for this device, based on the nature and duration of body contact.
Contact-based categorisation
Devices are classified by contact type (surface, external-communicating, implant) and duration (limited, prolonged, long-term). A blood-contact IV set faces very different endpoints from a short-use surface device.
Typical endpoints
Cytotoxicity, sensitisation, irritation, systemic toxicity, genotoxicity, and - for blood-contact devices - haemocompatibility, among others. Which apply depends on the categorisation above.
🧪 Chemical characterisation & extractables/leachables - where plasticizers matter most
Modern biological evaluation leans heavily on chemical characterisation (ISO 10993-18) and toxicological risk assessment (ISO 10993-17), reducing reliance on animal tests by focusing on what actually comes out of the material. That means extractables and leachables (E&L) testing - and a plasticizer is typically the single largest leachable in flexible PVC.
💡 This is the crux: a low-migration plasticizer produces fewer and lower leachables, which shrinks the E&L and toxicological-assessment burden. It is exactly why high-molecular-weight esters are favoured for the most demanding devices - see non-phthalate medical PVC plasticizers for the material side.
🇺🇸 The FDA pathway (US)
In the US, most devices reach market via 510(k) premarket notification (or PMA / De Novo for higher-risk or novel devices). Biocompatibility is part of that submission, and FDA's own guidance on ISO 10993-1 sets out how they expect the risk-based evaluation, chemical assessment and testing to be presented. A material with a clean toxicological profile and low leachables makes that dossier simpler to defend. 📄
🇪🇺 EU MDR - substances of concern
The EU Medical Device Regulation (2017/745) is stricter than the old MDD, and it directly addresses plasticizers. Its Annex I requires special justification and labelling when a device contains CMR or endocrine-disrupting substances above 0.1% by weight - for example, phthalates like DEHP. Choosing a non-CMR plasticizer such as TOPM avoids triggering that justification-and-labelling obligation entirely, which is a meaningful advantage under MDR. See the regulatory detail in Is TOPM REACH-compliant? ⚖️
🎯 How plasticizer choice affects compliance
| Requirement | How the plasticizer helps or hurts |
|---|---|
| ISO 10993 E&L burden | Low-migration ester → fewer/lower leachables to characterise |
| Toxicological risk assessment | Non-CMR profile → cleaner assessment, easier justification |
| EU MDR Annex I (10.4) | Non-CMR/non-ED → avoids the >0.1% justify-and-label trigger |
| Device stability / shelf life | Low volatility → properties hold through sterilisation & ageing |
The plasticizer supports compliance; it does not replace device-level testing.
🤝 What the supplier provides vs what the device maker must do
🔹 Supplier (material) side: SDS, composition/identity, non-CMR status, and any available migration/purity data that support your evaluation.
🔹 Device maker side: device-level biological evaluation under ISO 10993, E&L studies on the finished article, and the full premarket submission (FDA) or technical documentation (MDR). This is where compliance is ultimately proven.
💡 Important: whether a material passes depends on the whole formulation, process and finished device - supplier data supports your evaluation but does not replace device testing. Standards and regulations evolve; this article is general information, not legal or regulatory advice. Confirm current requirements and consult your regulatory team.
❓ Frequently asked questions
🔹 Is a plasticizer "ISO 10993 approved"?
No. ISO 10993 evaluates finished devices and their materials, not raw ingredients in isolation. A plasticizer can be well suited to medical use and supported by data, but the device is what undergoes biological evaluation.
🔹 Why does a low-migration plasticizer make compliance easier?
Because plasticizer is usually the biggest leachable in flexible PVC. Less migration means fewer and lower leachables to characterise and assess under ISO 10993-18/-17.
🔹 What does EU MDR say about phthalate plasticizers?
MDR Annex I requires justification and labelling for CMR or endocrine-disrupting substances present above 0.1%, which captures phthalates like DEHP. A non-CMR plasticizer avoids that trigger.
🔹 Does switching plasticizer require re-testing?
Yes. Any material change alters the finished device, so biocompatibility and E&L work must be repeated or bridged - plan a plasticizer change as a validation project.
🔗 Related articles
📞 Building a compliance case for a medical PVC device?
We supply non-CMR, low-migration plasticizers with the SDS, identity and material data to support your ISO 10993, FDA and MDR evaluation. Tell us your device and market and we'll send what your regulatory team needs.
